.jpg)
- Cancer biotherapy & radiopharmaceuticals
-
影响因子：
1.738
-
I S S N：
1084-9785
-
出 版 社：
Mary Ann Liebert, Inc
-
出 版 地：
Larchmont, NY
-
出版国家：
United States
-
刊 期：
双月刊
-
创刊时间：
1996
-
语 种：
英文
-
审稿周期：
平均3月
-
中科院分区：
4
-
投稿命中率：
命中率约95%
-
国外数据库收录：
IM
-
中国收录文章数：
153
-
5年影响因子：
1.685
-
研究领域：
生物制剂、肿瘤、核医学
-
官方链接：
http://online.liebertpub.com/cbr
-
投稿须知：
http://online.liebertpub.com/cbr
期刊介绍：
Cancer Biotherapy and Radiopharmaceuticals is the established peer-reviewed journal, with over 25 years of cutting-edge content on innovative therapeutic investigations to ultimately improve cancer management. It is the only journal with the specific focus of cancer biotherapy and is inclusive of monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapies.
The Journal includes extensive reporting on advancements in radioimmunotherapy, and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments.
Cancer Biotherapy and Radiopharmaceuticals coverage includes:
Antibody drug conjugates
Fusion toxins and immunotoxins
Nanoparticle therapy
Vascular therapy
Inhibitors of proliferation signaling pathways
Cancer Biotherapy and Radiopharmaceuticals is under the editorial leadership of Editors Donald J. Buchsbaum, PhD, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham; Robert K. Oldham, MD, Lower Keys Cancer Center; and other leading investigators. View the entire editorial
